Prevention Of Cmv Disease After Cardiac Transplantation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of cmv disease after cardiac transplantation. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
1
Active US patents
42/100
Avg vulnerability
—
Annual revenue covered

Originators in Prevention Of Cmv Disease After Cardiac Transplantation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche Palo 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of cmv disease after cardiac transplantation. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytovene
GANCICLOVIR
 Roche Palo 1 42 — 2034-09-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9486530 Cytovene formulation 42 2034-09-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9486530 Cytovene formulation 42 2034-09-02

Related